Salud financiera de hoja de balance de Abbott Laboratories
Salud financiera controles de criterios 6/6
Abbott Laboratories tiene un patrimonio de accionistas total de $38.8B y una deuda total de $15.9B, lo que sitúa su ratio deuda-patrimonio en 40.9%. Sus activos y pasivos totales son $73.2B y $34.4B respectivamente. El BAIT de Abbott Laboratories es de $7.1B, por lo que su ratio de cobertura de intereses es de 27.2. Tiene efectivo e inversiones a corto plazo que ascienden a $7.3B.
Información clave
37.7%
Ratio deuda-patrimonio
US$14.71b
Deuda
| Ratio de cobertura de intereses | 27.3x |
| Efectivo | US$6.65b |
| Patrimonio | US$39.04b |
| Total pasivo | US$33.42b |
| Activos totales | US$72.47b |
Actualizaciones recientes sobre salud financiera
Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06
Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt
Aug 13Recent updates
Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King
Dec 28Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Dec 27Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Dec 03Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market
Nov 26Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
Nov 01Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up
Oct 24Abbott: A Diversified Health Care Company With Strong Underlying Growth
Oct 20Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience
Sep 29Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price
Sep 26Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income
Sep 17We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt
Aug 13Abbott: This Dividend King Is Ready For Takeoff
Jul 31Abbott Laboratories Q2 2023 Earnings Preview: Expect Incremental Improvement
Jul 17The Big Trends: New Frontiers in Healthcare
Jul 13
Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital
Jul 12Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Jun 25Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($22.7B) de ABT superan a sus pasivos a corto plazo ($13.8B).
Pasivo a largo plazo: Los activos a corto plazo de ABT ($22.7B) superan a sus pasivos a largo plazo ($20.5B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (22.1%) de ABT se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de ABT ha pasado de 61.4% a 40.9% en los últimos 5 años.
Cobertura de la deuda: La deuda de ABT está bien cubierta por el flujo de caja operativo (45.7%).
Cobertura de intereses: Los pagos de intereses de la deuda de ABT están bien cubiertos por el BAIT (27.2x cobertura).